|
Aug 5
|
Here's Why Momentum in UCB (UCBJY) Should Keep going
|
|
Aug 5
|
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 18
|
Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth
|
|
Jun 27
|
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
|
|
May 19
|
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
|
|
Mar 12
|
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
|